Study of remibrutinib for severe itching of unknown cause
Treatments studied
Part of Skin clinical trials.
This study tests an investigational medicine (remibrutinib) for people with severe itching that has no known cause. It may help reduce the itch when moisturizers haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have had severe itching for at least 4 months.
- The cause of your itching is unknown (not from a skin condition, other illness, or medication).
- Your itching affects at least two large body areas like your trunk, arms, or legs.
- Your average daily itch score is 7 or higher on a 0-10 scale (10 is worst).
- You do not have active skin diseases (like eczema or psoriasis), certain infections, cancer (in the last 5 years), or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called remibrutinib to see if it can reduce severe itching that has no clear cause. It aims to help people whose daily itching is very intense and not relieved by standard creams.
This trial tests an investigational drug called ATTO-1310 to see if it can reduce chronic itching that has no clear cause. It may help people who have tried antihistamines without success.
This trial tests an experimental drug called Remibrutinib for people with chronic hives (urticaria) that are not well controlled with standard antihistamines. The goal is to see if the drug reduces symptoms like itching and wheals.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
This study follows people with chronic spontaneous urticaria (long-lasting hives with no clear cause) who are starting a new medicine called remibrutinib or dupilumab. It aims to see how well these treatments work in everyday life.
This study tests a new oral medication, remibrutinib, in adults with moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful lumps and tunnels. The goal is to see how the drug affects the skin tissue and to gather information for future treatments.
Hear when a new Chronic Pruritus of Unknown Origin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.